Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8108604 | 0.92 | NPC1 (0.69) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4496832 | 0.88 | NPC1 (0.57) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL2324292 | 0.87 | NPC1 (0.78) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4813791 | 0.87 | NPC1 (0.58) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL179157 | 0.85 | NPC1 (0.63) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL179162 | 0.85 | MGAM (0.61) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL30108052 | 0.85 | ALDH1A1 (0.58) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL179155 | 0.84 | CBFB (0.63) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL179158 | 0.84 | CBFB (0.65) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6262977 | 0.84 | NPC1 (0.79) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | claimed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | claimed |
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2009123776-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | HAVCR2, ZC3HAV1, SARS1 | ALDH1A1 2058/4885NPC1 54/4885RAB9A 3129/4885 |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | ZC3HAV1, EIF2AK2, SARS1 | ALDH1A1 2238/4885NPC1 164/4885RAB9A 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.